Network Medicine

Blueprint for antimicrobial hit discovery targeting metabolic networks

Proceedings of the National Academy of Sciences of the United States of America 10.1073, 1-6 (2010) Advances in genome analysis, network biology, and computational chemistry have the potential to revolutionize drug discovery by combining system-level identification of drug targets with the atomistic modeling of small molecules capable of modulating their activity. To demonstrate the effectiveness of such a discovery pipeline, we deduced common antibiotic targets in Escherichia coli and Staphylococcus aureus by identifying shared tissue-specific or uniformly essential metabolic reactions in their metabolic networks. We then predicted through virtual screening dozens of potential inhibitors for several enzymes of these reactions and showed experimentally that a subset of these inhibited both enzyme activities in vitro and bacterial cell viability. This blueprint is applicable for any sequenced organism with high-quality metabolic reconstruction and suggests a general strategy for strain-specific antiinfective therapy.


More publications
C.A. Hidalgo, R. B. Klinger, A.-L. Barabási, R. Hausmann

Science 317, 482 (2007)

M. A. Yildirim, K.-L. Goh, M.E. Cusick, A.-L. Barabási, M. Vidal

Nature Biotechnology 25:10, 1119-1126 (2007)

A. Vazquez, M. A. de Menezes, A.-L. Barabási, Z. N. Oltvai

PLoS Computational Biology 4:10, 1-6 (2008)